Intensity Therapeutics, Inc.
Pharmaceutical ManufacturingConnecticut, United States11-50 Employees
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on immune-based therapies for solid tumors within the pharmaceutical sector. It has developed a proprietary intratumoral delivery approach that, after direct injection, rapidly disperses throughout the tumor and diffuses therapeutic agents into cancer cells. Its lead candidate, INT230-6, is being evaluated in a Phase 1/2 study across multiple advanced solid tumors, with the potential to stimulate an adaptive immune response that may target both injected tumors and distant sites. The company is based in Shelton, Connecticut, and operates with a small-to-mid-sized team pursuing clinical development programs and collaborations. A notable recent development is a collaboration with the Swiss Group for Clinical Cancer Research (SAKK) to conduct a Phase II randomized trial in early-stage triple-negative breast cancer in Europe.
1-888-653-2347 
support@leadiq.com 
